| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Investigative Ophthalmology & Visual Science, Vol 38, 1639-1646, Copyright © 1997 by Association for Research in Vision and Ophthalmology
ARTICLES AND REPORTS |
MF Cordeiro, PH Constable, RA Alexander, SS Bhattacharya and PT Khaw
Wound Healing Group, Institute of Opthalmology, London, England.
PURPOSE: To investigate the effect of varying the treatment area of subconjunctival mitomycin-C (MMC) using an adapted rabbit model of filtration surgery. METHODS: Twenty-four New Zealand White rabbits underwent filtration surgery, with random allocation to one of three treatments: 5-minute subconjunctival applications of MMC (0.4 mg/ml) with either a large (8 x 10 mm) or small (4 x 2 mm) sponge or no treatment (control). Drainage was achieved by placing an intravenous cannula through a scleral tunnel into the anterior chamber. Rabbits were examined at set intervals for up to 30 days after surgery. Measurements of appearance, size, height, and vascularity of blebs and of intraocular pressure and anterior chamber depth were made by a masked observer. Histologic analysis of eyes was performed at 3, 14, and 30 days. RESULTS: Statistical analysis showed a significant difference in bleb survival among all groups (log rank P = 0.0054, with 100% survival with large areas of MMC treatment). Comparison between large and small treatment area groups revealed significant differences in bleb survival (log rank P = 0.0388); bleb area (between-subject analysis, P = 0.009), and bleb height (between-subject analysis, P = 0.005). These differences were seen clinically, with large areas of MMC treatment producing diffuse and elevated blebs, small areas of treatment producing thin-walled and localized blebs with scarring at 21 days, and no treatment resulting in comparatively vascularized and scarred blebs before 14 days. Histologic analysis revealed clear differences among groups, with an increase in subconjunctival cellularity and scar tissue in eyes with failed blebs. CONCLUSIONS: The size of the area of subconjunctival MMC treatment significantly affects surgical outcome. Histologic features mirror differences observed clinically. Alteration of the size of the MMC treatment area may provide an alternative and more controllable approach to modulating the wound-healing response after drainage surgery and, more important in the clinical context, to modifying bleb morphology.
This article has been cited by other articles:
|
|
 |
|
  N Anand, S Arora, and M Clowes Mitomycin C augmented glaucoma surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and leaks Br. J. Ophthalmol., February 1, 2006; 90(2): 175 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. T. L. Wong, A. L. Mead, and P. T. Khaw Prolonged Antiscarring Effects of Ilomastat and MMC after Experimental Glaucoma Filtration Surgery Invest. Ophthalmol. Vis. Sci., June 1, 2005; 46(6): 2018 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Esson, M. P. Popp, L. Liu, G. S. Schultz, and M. B. Sherwood Microarray Analysis of the Failure of Filtering Blebs in a Rat Model of Glaucoma Filtering Surgery Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4450 - 4462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Esson, A. Neelakantan, S. A. Iyer, T. D. Blalock, L. Balasubramanian, G. R. Grotendorst, G. S. Schultz, and M. B. Sherwood Expression of Connective Tissue Growth Factor after Glaucoma Filtration Surgery in a Rabbit Model Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 485 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Barton, D. L. Budenz, P. T. Khaw, and S. C. G. Tseng Glaucoma Filtration Surgery using Amniotic Membrane Transplantation Invest. Ophthalmol. Vis. Sci., July 1, 2001; 42(8): 1762 - 1768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Chang, J. G. Crowston, C. A. Sabin, P. T. Khaw, and A. N. Akbar Human Tenon's Fibroblast-Produced IFN{beta} and the Prevention of T-Cell Apoptosis Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1531 - 1538. [Abstract] [Full Text]
|
|
|
|
|
|
O. J Lehmann, C. Bunce, M. M Matheson, V. Maurino, P. T Khaw, R. Wormald, and K. Barton Risk factors for development of post-trabeculectomy endophthalmitis Br. J. Ophthalmol., December 1, 2000; 84(12): 1349 - 1353. [Abstract] [Full Text]
|
|
|
|
|
|
M. R Wilkins, N. L Occleston, A. Kotecha, L. Waters, and P. T Khaw Sponge delivery variables and tissue levels of 5-fluorouracil Br. J. Ophthalmol., January 1, 2000; 84(1): 92 - 97. [Abstract] [Full Text]
|
|
|
|
|
|
M F. CORDEIRO, G. S SCHULTZ, R. R ALI, S. S BHATTACHARYA, and P. T KHAW Molecular therapy in ocular wound healing Br. J. Ophthalmol., November 1, 1999; 83(11): 1219 - 1224. [Full Text]
|
|
|
|
|
|
M. F. Cordeiro, J. A. Gay, and P. T. Khaw Human Anti-Transforming Growth Factor-{beta}2 Antibody: A New Glaucoma Anti-Scarring Agent Invest. Ophthalmol. Vis. Sci., September 1, 1999; 40(10): 2225 - 2234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Cordeiro, M. B. Reichel, J. A. Gay, F. D’Esposita, R. A. Alexander, and P. T. Khaw Transforming Growth Factor-{beta}1, -{beta}2, and -{beta}3 In Vivo: Effects on Normal and Mitomycin C-Modulated Conjunctival Scarring Invest. Ophthalmol. Vis. Sci., August 1, 1999; 40(9): 1975 - 1982. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
